JACKSONVILLE, Fla., Nov. 8, 2016 /PRNewswire/ -- TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced that its common stock has commenced trading on The Nasdaq Capital Market from the opening of market today. The company’s common stock will trade under the symbol “TPIV”.
Nasdaq is home to more than 3,400 listed companies with a market value of over $8.5 trillion.
About TapImmune Inc.
TapImmune Inc. is an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines technologies for the treatment of cancer and metastatic disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Immuno-oncology has become the most rapidly growing sector in the pharmaceutical and biotech industry. Please visit the Company’s website at http://www.tapimmune.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV 200, the Company’s ability to raise future financing for continued development and the ability to successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20161031/434434LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-commences-trading-on-the-nasdaq-capital-market-300359169.html
SOURCE TapImmune, Inc.
